TARRYTOWN, N.Y., June 02, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused
on developing innovative medicines and other products for targeting and treating cancer, announced today that Mark R. Baker, Chief
Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 11:30 a.m. Eastern Time.
The conference is being held at the Grand Hyatt in New York, NY.
A live webcast of the Jefferies presentation will be available in the Media Center of the Progenics
website, www.progenics.com. To ensure a timely connection, users should register at least 15 minutes prior
to the scheduled start. An archive of the event will be available for 90 days.
About Progenics
Progenics Pharmaceuticals, Inc. is developing innovative medicines and other products for targeting and treating
cancer, with a pipeline that includes several product candidates in later-stage clinical development. These products in development
include therapeutic agents designed to precisely target cancer (AZEDRA® and 1095), and PSMA-targeted imaging agents for
prostate cancer (1404 and PyLTM) intended to enable clinicians and patients to accurately visualize and manage their
disease. Progenics recently entered into an agreement with a subsidiary of Bayer AG granting Bayer exclusive worldwide rights to
develop and commercialize products using our PSMA antibody technology in combination with alpha-emitting radionuclides. In
addition, in late 2015 Progenics acquired EXINI Diagnostics AB, a leader in the development of advanced artificial
intelligence-based imaging analysis tools and solutions for medical decision support. The acquisition of EXINI complements
Progenics’ strategy to support its imaging and therapeutic agents with sophisticated analytical tools and other technologies to
help physicians and patients visualize, understand, target and treat cancer. Progenics’ first commercial product,
RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Valeant
Pharmaceuticals International, Inc.
This press release may contain projections and other "forward-looking statements" regarding future events.
Statements contained in this communication that refer to Progenics' estimated or anticipated future results or other non-historical
facts are forward-looking statements that reflect Progenics' current perspective of existing trends and information as of the date
of this communication. Forward looking statements generally will be accompanied by words such as "anticipate," "believe," "plan,"
"could," "should," "estimate," "expect," "forecast," "outlook," "guidance," "intend," "may," "might," "will," "possible,"
"potential," "predict," "project," or other similar words, phrases or expressions. Such statements are predictions only, and are
subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties
include, among others, the cost, timing and unpredictability of results of clinical trials and other development activities and
collaborations, such as the Phase 3 clinical program for 1404; our ability to successfully integrate EXINI Diagnostics AB and to
develop and commercialize its products; the unpredictability of the duration and results of regulatory review of New Drug
Applications and Investigational NDAs; market acceptance for approved products; the sales of products by our partners and the
royalty revenue generated thereby; generic and other competition; the possible impairment of, inability to obtain and costs of
obtaining intellectual property rights; possible product safety or efficacy concerns, general business, financial and accounting
matters, litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its
website, and in its press releases and reports it files with the U.S. Securities and Exchange Commission. Progenics is providing
the information in this press release as of its date and, except as expressly required by law, Progenics disclaims any intent or
obligation to update or revise any forward-looking statements, whether as a result of new information, future events or
circumstances or otherwise.
Additional information concerning Progenics and its business may be available in press releases or other
public announcements and public filings made after this release. For more information, please visit www.progenics.com. Please follow us on LinkedIn®. Information on or
accessed through our website or social media sites is not included in the company's SEC filings.
(PGNX-F)
Contact: Melissa Downs Investor Relations (914) 789-2801 mdowns@progenics.com
